GET DAILY SIGNALSSANUWAVE Health (SNWV) Prepares for Third-Quarter 2026 Earnings Amid Recovery Efforts
Key Takeaways
- SANUWAVE Health is expected to report third-quarter 2026 results, with a conference call scheduled for November 11, 2026.
- Wall Street consensus calls for earnings of roughly $0.01 per share and revenue near $13.75 million, versus $0.46 in EPS and $11.45 million in revenue a year ago.
- The company's second quarter showed softer results, with revenue down 3% year over year and an EPS miss, making the third quarter a key test of its recovery narrative.
- Investors will focus on recurring consumables (applicator) growth, system sales trends, and gross margin as the company navigates reseller and reimbursement shifts.
- Proposed Medicare reimbursement changes from the Centers for Medicare & Medicaid Services (CMS) remain the biggest swing factor for the company's 2027 outlook.
- For more detail, explore SANUWAVE Health's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover additional market ideas by exploring Trending AI Robots.
Why This Earnings Report Matters
SANUWAVE Health, a medical device company focused on advanced wound care, is at a pivotal moment as it heads into its third-quarter 2026 report. The company's UltraMIST directed-energy system has driven strong recurring consumables demand, but recent quarters have been pressured by weaker capital-equipment sales and an evolving reimbursement landscape. The second quarter of 2026 brought a year-over-year revenue decline and an earnings miss, tempering investor optimism. Now, the third-quarter update will reveal whether management can reignite growth, defend margins, and clarify its path against proposed CMS rate changes. For shareholders, the report serves as both a measure of execution and a signal of how the business may fare into 2027.
Earnings Expectations
Analysts expect SANUWAVE Health to report earnings of approximately $0.01 per share on revenue of about $13.75 million for the third quarter of 2026. That compares with earnings of $0.46 per share and revenue of $11.45 million in the same period a year earlier, implying a projected revenue increase of roughly 20% even as earnings per share (EPS) are expected to decline sharply. For context, the company posted revenue of $9.74 million and a loss of $0.08 per share in the second quarter of 2026, missing consensus EPS of negative $0.03. The company has reiterated a full-year 2026 revenue outlook in the range of $51 million to $55 million. Key metrics to watch include consumables and applicator volume growth, system sales, gross margin, operating expenses, and cash position. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment heading into the third-quarter report is cautious. SANUWAVE Health shares have experienced significant volatility in 2026, reflecting both a challenging start to the year and growing uncertainty over Medicare reimbursement for its UltraMIST treatments. The second-quarter revenue decline and EPS miss weighed on confidence, and investors now appear focused less on near-term headline figures than on the durability of consumables demand and management's response to proposed CMS rate cuts. Key risk factors include the timing of a final CMS ruling, potential pressure on average selling prices, and the pace of system sales recovery. A clean beat on revenue alongside stable or improving gross margin would likely be viewed favorably, while further erosion in system sales or a downbeat reimbursement read could reinforce bearish sentiment.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most consequential issue for SANUWAVE Health is the regulatory environment. CMS has proposed changes to the 2027 physician fee schedule that would reduce reimbursement for the 97610 billing code associated with UltraMIST, while separately proposing a roughly 14% increase in hospital outpatient settings. Because these are proposed rather than final rules, management and investors will be watching for the final determination, expected around early November.
Beyond regulation, investors should monitor the company's recurring revenue engine. Consumables and applicator sales have been the bright spot, rising even as capital-equipment system sales softened. Continued volume growth in consumables would support the idea of a durable installed base and recurring revenue stream. At the same time, gross margin has slipped modestly as the revenue mix shifts toward lower-margin consumables and reseller channels, so margin stability will be an important indicator of operating leverage.
Finally, watch the cash position, operating expense trends, and any updates to full-year guidance. Management has emphasized disciplined spending even as it invests in research and development and commercialization. The third-quarter report and accompanying commentary should clarify whether the company remains on track for its full-year revenue range and how it plans to navigate a potentially tougher reimbursement environment in 2027.
Tools That Support My Research Process
In my own analysis, I often turn to Tickeron’s AI Screener to filter opportunities across the medical-device sector. It helps surface trends and patterns more efficiently than manual methods, giving clearer context on names like SANUWAVE Health relative to peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SNWV's Stochastic Oscillator dives into oversold zone
The Stochastic Oscillator for SNWV moved into oversold territory on November 06, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +15.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNWV advanced for three days, in 160 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNWV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 74 of 83 cases where SNWV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNWV as a result. In 121 of 128 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SNWV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 65 similar instances when the indicator turned negative. In 59 of the 65 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SNWV moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SNWV crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNWV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.760) is normal, around the industry mean (4.137). P/E Ratio (1.230) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.873) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. SNWV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNWV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement